Conclusions.
Chagas disease
CHAGAS DISEASE
This study confirms the efficacy and safety of a pediatric formulation of nifurtimox administered in an age- and weight-adjusted regimen for 60 days to treat Chagas disease in pediatric patients with 4-year follow-up data. Children younger than 2 years treated with nifurtimox are more likely to show seronegative conversion than older children during a relatively short posttreatment follow-up observation. Reduction of ELISA OD values and consecutive negative 